FMC and Ballagro sign agreement to expand biological solutions in Brazil

FMC Corporation announced an agreement with Ballagro Agro Tecnologia Ltda to offer differentiated biological products to Brazilian farmers. The partnership is part of FMC’s strategy to expand its biological platform in key markets, such as Brazil.

According to the announcement, the alliance combines the technical expertise of the two companies: FMC, focused on microbial solutions, and Ballagro, a specialist in fungi-based technologies. Together, they seek to strengthen the biosolutions sector in the country, expanding producers' access to superior crop protection technologies.

Bénédicte Flambard, Vice President of FMC Plant Health, highlighted the relevance of the agreement for the company's global growth in the plant health sector: "FMC and Ballagro offer a differentiated portfolio and innovative technologies. By joining knowledge and forces, we can redefine the biosolutions scenario in Brazil."

The partnership is part of FMC’s investment in its plant health line, which integrates biological, synthetic and precision agriculture solutions. The approach seeks integrated pest management. With the agreement, the companies hope to improve the productivity, efficiency and sustainability of Brazilian crops.

Renato Guimarães, vice president and president of FMC Latin America, said that the demand for new technologies that sustainably protect crops has been increasing. "The partnership with Ballagro reinforces our strategy in Brazil, bringing innovative solutions that meet the needs of producers," he said.

Arnelo Nedel, Ballagro's commercial director, highlighted Brazil's role as a reference in the use of biological control: "this agreement is an important step towards bringing advanced technologies and knowledge to Brazilian farmers. The union of innovation and expertise between Ballagro and FMC will drive the development of cutting-edge solutions that promote sustainable agriculture."

FMC has a strong presence in Brazil. The company reported that in the last five years it has launched around 50 biological products in 42 countries. Its plans involve investing in research and development, strategic partnerships and the commercialization of its own technologies, such as its pheromone platform.